On Jul. 6, 2020, the FDA issued an emergency use authorization (EUA) for the third diagnostic test for detection and differentiation of the viruses that cause flu and COVID-19 in individuals suspected of COVID-19 by their healthcare provider to the Centers for Disease Control and Prevention.

To date, the FDA had authorized 164 tests under EUAs; these included 137 molecular tests, 25 antibody tests, and 2 antigen tests.